WHAT IS CLAIMED:

1. A compound according to the following formula (SEQ ID NO: 1016):



or a pharmaceutically acceptable salt thereof.

2. A compound or a pharmaceutically acceptable salt thereof, comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide is 16 linked nucleosides in length and has the nucleobase sequence consisting of the nucleobase sequence of SEQ ID NO: 1016, wherein the modified oligonucleotide has

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage; wherein each cytosine is a 5-methylcytosine.

3. The compound of claim 1, wherein the pharmaceutically acceptable salt is a sodium salt.

4. The compound of claim 1, wherein the pharmaceutically acceptable salt is a potassium salt.

5. A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6. A compound consisting of a modified oligonucleotide, wherein the modified oligonucleotide is 16 linked nucleosides in length and consists of the sequence of SEQ ID NO: 1016, wherein the modified oligonucleotide consists

of a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

7. The compound of claim 2, wherein the pharmaceutically acceptable salt is a sodium salt.

8. The compound of claim 2, wherein the pharmaceutically acceptable salt is a potassium salt.

9. A composition comprising the compound of claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. The compound of claim 2, wherein the conjugate group is 5'-Trishexylamino-(THA)-C_6GalNAC3 and is linked to the modified oligonucleotide at the 5' end of the modified oligonucleotide.